NuCana 관리

관리 기준 확인 3/4

NuCana CEO는 Hugh Griffith, Mar2008 에 임명되었습니다 의 임기는 16.67 년입니다. 총 연간 보상은 £ 974.59K, 58.9% 로 구성됩니다. 58.9% 급여 및 41.1% 보너스(회사 주식 및 옵션 포함). 는 $ 63.76K 가치에 해당하는 회사 주식의 2.25% 직접 소유합니다. 63.76K. 경영진과 이사회의 평균 재임 기간은 각각 4.1 년과 6.5 년입니다.

주요 정보

Hugh Griffith

최고 경영자

UK£974.6k

총 보상

CEO 급여 비율	58.9%
CEO 임기	16.7yrs
CEO 소유권	2.3%
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Hugh Griffith 의 보수는 NuCana 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-UK£26m
Jun 30 2024	n/a	n/a	-UK£28m
Mar 31 2024	n/a	n/a	-UK£27m
Dec 31 2023	UK£975k	UK£574k	-UK£28m
Sep 30 2023	n/a	n/a	-UK£35m
Jun 30 2023	n/a	n/a	-UK£33m
Mar 31 2023	n/a	n/a	-UK£31m
Dec 31 2022	UK£1m	UK£552k	-UK£32m
Sep 30 2022	n/a	n/a	-UK£30m
Jun 30 2022	n/a	n/a	-UK£34m
Mar 31 2022	n/a	n/a	-UK£39m
Dec 31 2021	UK£907k	UK£531k	-UK£41m
Sep 30 2021	n/a	n/a	-UK£39m
Jun 30 2021	n/a	n/a	-UK£40m
Mar 31 2021	n/a	n/a	-UK£36m
Dec 31 2020	UK£920k	UK£551k	-UK£31m
Sep 30 2020	n/a	n/a	-UK£26m
Jun 30 2020	n/a	n/a	-UK£22m
Mar 31 2020	n/a	n/a	-UK£20m
Dec 31 2019	UK£828k	UK£498k	-UK£21m
Sep 30 2019	n/a	n/a	-UK£17m
Jun 30 2019	n/a	n/a	-UK£16m
Mar 31 2019	n/a	n/a	-UK£13m
Dec 31 2018	UK£786k	UK£467k	-UK£14m
Sep 30 2018	n/a	n/a	-UK£15m
Jun 30 2018	n/a	n/a	-UK£26m
Mar 31 2018	n/a	n/a	-UK£28m
Dec 31 2017	UK£635k	UK£330k	-UK£23m

보상 대 시장: Hugh 의 총 보상 ($USD 1.22M )은 US 시장( $USD 646.00K ).

보상과 수익: Hugh 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Hugh Griffith (56 yo)

16.7yrs

테뉴어

UK£974,586

보상

Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hugh Griffith	Founder	16.7yrs	UK£974.59k	2.25% $ 63.8k
Donald Munoz	Chief Financial Officer	9.1yrs	데이터 없음	0.28% $ 7.8k
David Harrison	Head of Translational Medicine	6.9yrs	데이터 없음	0% $ 0
Jeffrey Bloss	Chief Medical Officer	3.3yrs	데이터 없음	0.00018% $ 5.1
Theresa Bruce	Senior Vice President of Clinical Operations	4.8yrs	데이터 없음	데이터 없음
Elisabeth Oelmann	Senior Vice President of Medical & Clinical Development	4.1yrs	데이터 없음	데이터 없음
John-Paul Gallivan	Senior VP of Strategy & Lifecycle Management	less than a year	데이터 없음	데이터 없음
Gordon Kennovin	Senior VP of CMC & Development	less than a year	데이터 없음	데이터 없음
Stuart Grant	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	데이터 없음
Martin Quinn	Company Secretary	no data	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: NCNA 의 관리팀은 경험 ( 4.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hugh Griffith	Founder	16.7yrs	UK£974.59k	2.25% $ 63.8k
Andrew Kay	Independent Non-Executive Chairman	3.9yrs	UK£78.77k	0% $ 0
Martin Mellish	Independent Non-Executive Director	14.9yrs	UK£47.85k	0.050% $ 1.4k
Adam George	Independent Non Executive Director	6.6yrs	UK£56.56k	0% $ 0
Balaji Muralidhar	Independent Non-Executive Director	4.2yrs	UK£29.25k	0.00098% $ 27.7
Elliott Levy	Independent Director	3yrs	UK£54.23k	0.0084% $ 236.9
Cyrille Leperlier	Independent Non Executive Director	6.5yrs	UK£65.08k	0% $ 0

6.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: NCNA 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.

NuCana 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

NuCana plc, Annual General Meeting, Jun 15, 2023

Less than half of directors are independent

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

Recent updates

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

New minor risk - Shareholder dilution

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간